Petros Grivas, MD, PhD, discusses posthoc findings from the phase 3 JAVELIN Bladder 100 trial presented during the 2021 ASCO Annual Meeting. Based on the primary findings from the trial, the FDA previously approved avelumab (Bavencio) as a frontline maintenance therapy in patients with advanced urothelial cancer that has not progressed with first-line platinum-based chemotherapy.
Grivas is global co-principal investigator on the JAVELIN Bladder 100 trial and associate professor and clinical director of the Genitourinary Cancers Program at Seattle Cancer Care Alliance, and associate professor, Division of Medical Oncology, University of Washington School of Medicine.
Data support shock wave lithotripsy for pediatric patients with kidney stones
May 28th 2024Regarding patient-reported outcomes, those who underwent URS showed higher urinary symptoms, greater pain intensity, and greater pain interference at 1 week following surgery compared with those who underwent SWL.